Online citations, reference lists, and bibliographies.
← Back to Search

Development And Characterization Of Cyclosporine A Loaded Nanoparticles For Ocular Drug Delivery: Cellular Toxicity, Uptake, And Kinetic Studies.

P. Aksungur, Murat Demirbilek, E. Denkbaş, J. Vandervoort, A. Ludwig, Nurşen Unlü
Published 2011 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Dry eye syndrome is a common disorder of the tear film caused by decreased tear production or increased evaporation. The objective of this study was to evaluate the potential effectiveness of Cyclosporine A (CsA) nanoparticles (NPs) for the treatment of inflammation of the eye surface. Topical CsA is currently the only and safe pharmacologic treatment of severe dry eye symptoms. The NPs were prepared using either poly-lactide-co-glycolide (PLGA) or a mixture of PLGA with Eudragit®RL or were coated with Carbopol®. The mean size of CsA loaded NPs was within the range from 148 to 219nm, except for the Carbopol® coated NPs (393nm). The drug entrapment efficiency was very high (from 83 to 95%) and production yield was found between 75 and 92% in all preparations. The zeta potential of the Eudragit® RL containing NPs was positive (19-25mV). The NPs formulations exhibited a biphasic drug release with initial burst followed by a very slow drug release and total cumulative release within 24h ranged from 75 to 90%. Kinetically, the release profiles of CsA from NPs appeared to fit best with the Weibull model. The viability of L929 cells was decreased by increasing the concentration of the various NPs examined as well as the incubation time. The amount of NPs uptake was related to the polymer type used. The highest degree of cellular uptake (52.2%), tear film concentration of the drug (366.3ng/g) and AUC(0→24) (972.6ngh/g) value were obtained from PLGA: Eudragit® RL (75:25)-CsA NPs formulations. The change of surface characteristics of NPs represents a useful approach for improvement of ocular retention and drug availability.
This paper references
10.1002/JPS.1075
Controlled drug release from gels using surfactant aggregates: I. Effect of lipophilic interactions for a series of uncharged substances.
M. Paulsson (2001)
10.1016/0167-5699(92)90111-J
The mechanism of action of cyclosporin A and FK506.
S. Schreiber (1992)
10.1016/S0939-6411(00)00125-9
Freeze-drying of polycaprolactone and poly(D,L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs.
A. Saez (2000)
10.1080/10611860701453125
Piroxicam nanoparticles for ocular delivery: Physicochemical characterization and implementation in endotoxin-induced uveitis
Khosro Adibkia (2007)
10.1016/J.IJPHARM.2004.05.006
pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A.
Jundong Dai (2004)
Evaluation of cipro fl oxacinloaded Eudragit ® RS 100 or RL 100 / PLGA nanoparticles
J. Vandervoort K. Dillen (2001)
10.1016/J.IJPHARM.2007.07.041
Adhesion of PLGA or Eudragit/PLGA nanoparticles to Staphylococcus and Pseudomonas.
K. Dillen (2008)
10.1016/j.nano.2008.11.004
Formation of simvastatin nanoparticles from microemulsion.
K. Margulis-Goshen (2009)
Influence of topically applied cyclosporin A in olive oil on corneal epithelium
J. M. Benítez del Castillo (1994)
The mechanism of action of cyclosporine-A and FK506
S. L. Schreiber (1992)
10.1016/0169-409X(95)00017-2
Microspheres and nanoparticles used in ocular delivery systems
A. Zimmer (1995)
A comparative rheological study on carbopol viscous solutions and, the evaluation of their suitability as the ophthalmic vehicles and artificial tears.
N. Unlü (1992)
10.1016/j.biomaterials.2008.09.016
Multi-morphological biodegradable PLGE nanoparticles and their drug release behavior.
Hanwei Zhang (2009)
10.1007/s10856-008-3656-2
Investigation of polymeric amphiphilic nanoparticles as antitumor drug carriers
J. Zhang (2009)
10.3109/08982108909036000
Adhesion of Positively Charged Liposomes to Mucosal Tissues
L. S. Guo (1989)
Controlled drug release from gels using surfactant aggregates: I
M. Paulsson (2001)
10.1016/J.EXER.2003.09.003
The role of the lacrimal functional unit in the pathophysiology of dry eye.
M. Stern (2004)
10.1016/S0939-6411(03)00138-3
Cyclosporine A delivery to the eye: a pharmaceutical challenge.
F. Lallemand (2003)
10.1515/9783111548050-024
M
M. Sankar (1824)
10.1097/00003226-199403000-00006
Influence of Topically Applied Cyclosporine A in Olive Oil on Corneal Epithelium Permeability
J. M. Benítez Del Castillo (1994)
10.1016/S0002-9394(00)00625-5
Unusual corneal deposit after the topical use of cyclosporine as eyedrops.
S. Kachi (2000)
Modeling and comparison of dissolution pro fi les , Eur
J. M. Sousa Lobo P. Costa (2001)
10.1248/CPB.52.1273
Influence of the homogenisation procedure on the physicochemical properties of PLGA nanoparticles.
J. Vandervoort (2004)
10.1081/DDC-120014576
Low Molecular Weight Heparin-Loaded Polymeric Nanoparticles: Formulation, Characterization, and Release Characteristics
V. Hoffart (2002)
Low molecular weight heparinloaded polymeric nanoparticles: formulation
V. Hoffart (2002)
Formulation of Carbopol 940 ophthalmic vehicles, and in vitro evaluation of the influence of simulated lacrimal fluid on their physico-chemical properties.
N. Unlü (1991)
10.1016/J.IJPHARM.2006.01.041
Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles.
K. Dillen (2006)
10.1515/9783111576855-012
G
G.V.T.V. Weerasooriya (1824)
The mechanism of action of cyclosporineA and FK 506 , Immunol
G. R. Crabtree S. L. Schreiber (1990)
10.1248/CPB.57.657
Particle characterization of poorly water-soluble drugs using a spray freeze drying technique.
M. Kondo (2009)
10.1007/s11095-007-9400-7
Immunocolloidal Targeting of the Endocytotic Siglec-7 Receptor Using Peripheral Attachment of Siglec-7 Antibodies to Poly(Lactide-co-Glycolide) Nanoparticles
C. Scott (2007)
10.1097/00003226-200009000-00009
The Diagnosis and Management of Dry Eye: A Twenty-five–Year Review
S. Pflugfelder (2000)
10.1016/J.AJO.2003.10.036
Antiinflammatory therapy for dry eye.
S. Pflugfelder (2004)
10.1515/9783111576855-015
J
Seguin Hen (1824)
10.1080/03639040600975147
Preparation of Azithromycin Nanosuspensions by High Pressure Homogenization and its Physicochemical Characteristics Studies
Dianrui Zhang (2007)
10.1016/S0928-0987(01)00095-1
Modeling and comparison of dissolution profiles.
P. Costa (2001)
10.1016/b978-0-12-384931-1.00016-7
P
J. Lackie (2013)
10.1007/BF00180747
Progress towards a molecular understanding of cyclosporin A-mediated immunosuppression
A. Schumacher (1992)
10.1016/S0378-5173(01)00760-8
Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A.
A. M. de Campos (2001)
10.3109/10611869609046266
Biliary excretion of polystyrene microspheres with covalently linked FITC fluorescence after oral and parenteral administration to male Wistar rats.
P. U. Jani (1996)
10.1016/J.ADDR.2005.07.005
The use of mucoadhesive polymers in ocular drug delivery.
A. Ludwig (2005)
10.1016/0022-1759(89)90397-9
Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.
M. Hansen (1989)
10.1016/b978-0-12-384931-1.00003-9
C
J. Lackie (2013)
10.1016/S0928-0987(02)00057-X
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
R. Pignatello (2002)
10.1016/0378-5173(87)90050-0
A γ-scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles
P. Fitzgerald (1987)
10.1097/00003226-199007000-00002
Update on topical cyclosporin A. Background, immunology, and pharmacology.
M. Belin (1990)
10.1016/0378-5173(94)90179-1
Study of the mechanism of interaction of poly(ϵ-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy
P. Calvo (1994)
Antitumor effect of adriamycinencapsulated nanoparticles of poly ( DLlactidecoglycolide )grafted dextran
J. Y. Bang (2009)
10.1076/CEYR.17.1.39.5251
Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat.
J. R. Juberías (1998)
10.1002/jps.21588
Antitumor effect of adriamycin-encapsulated nanoparticles of poly(DL-lactide-co-glycolide)-grafted dextran.
K. Choi (2009)



This paper is referenced by
10.1016/j.ijpharm.2019.03.022
A novel FK506 loaded nanomicelles consisting of amino-terminated poly(ethylene glycol)-block-poly(D,L)-lactic acid and hydroxypropyl methylcellulose for ocular drug delivery.
Dong Liu (2019)
10.3109/03639045.2013.814061
Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study
J. Singh (2014)
10.1080/10837450.2016.1245742
Development and effect of storage on the stability of enriched flavonoid fraction of Cecropia glaziovii-loaded PLGA nanoparticles
T. Santos (2016)
10.1007/s40005-014-0129-0
The effect of Eudragit type on BSA-loaded PLGA nanoparticles
Min-Ho Park (2014)
10.1038/srep12968
Nanomicelle formulation for topical delivery of cyclosporine A into the cornea: in vitro mechanism and in vivo permeation evaluation
Chuanlong Guo (2015)
10.1016/J.PROGPOLYMSCI.2014.07.010
Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review
A. Sosnik (2014)
10.1002/jps.23780
Sustained release of naltrexone from poly(n-isopropylacrylamide) microgels.
A. Kjøniksen (2014)
10.1517/17425247.2014.938045
Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions
P. Suresh (2014)
10.1016/B978-0-12-802926-8.00025-2
Nanomedicines for the Eye: Current Status and Future Development
A. Attama (2016)
10.1016/j.ejps.2017.01.013
Studying the influence of formulation and process variables on Vancomycin‐loaded polymeric nanoparticles as potential carrier for enhanced ophthalmic delivery
Carol Yousry (2017)
10.3109/10837450.2012.705298
Preparation and characterization of polymeric and lipid nanoparticles of pilocarpine HCl for ocular application
Genç Lütfi (2013)
10.1007/978-3-319-58290-0
Pharmacologic Therapy of Ocular Disease
S. Whitcup (2017)
AN OVERVIEW ON EUDRAGIT BASED NANOPARTICULATE DRUG DELIVERY CARRIERS FOR OCULAR DELIVERY
P. Verma (2012)
10.1007/978-3-319-47691-9_9
Progress of Controlled Drug Delivery Systems in Topical Ophthalmology: Focus on Nano and Micro Drug Carriers
Ameeduzzafar Zafar (2016)
10.1016/j.exer.2016.04.016
Treatment of alkali-injured cornea by cyclosporine A-loaded electrospun nanofibers - An alternative mode of therapy.
J. Cejková (2016)
10.1007/s11095-017-2155-x
Cyclosporine A Loaded Electrospun Poly(D,L-Lactic Acid)/Poly(Ethylene Glycol) Nanofibers: Drug Carriers Utilizable in Local Immunosuppression
J. Širc (2017)
Development In Vitro and Biological Evaluation of Chitosan Reinforced Eudragit® RL 100 Nanoparticles for the Improvement of Ocular Bioavailability of Acetazolamide
P. Verma (2014)
10.1016/j.drudis.2016.04.002
Modern approaches to the ocular delivery of cyclosporine A.
P. Agarwal (2016)
Design and development of a novel artificial Bruch's membrane for ocular-based therapies
Gareth P. Ward (2016)
10.2147/IJN.S157566
Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis
M. Naeem (2018)
10.1208/s12249-015-0354-5
Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate
X. Yang (2015)
10.3390/pharmaceutics11030103
Development of Novel EE/Alginate Polyelectrolyte Complex Nanoparticles for Lysozyme Delivery: Physicochemical Properties and In Vitro Safety
Sabrina Sepúlveda-Rivas (2019)
10.3109/10717544.2014.923065
Colloidal drug delivery system: amplify the ocular delivery
Ameeduzzafar (2016)
BRITISH BIOMEDICAL BULLETIN
Vaishali Narayanrao Solanke (2014)
10.1016/J.COLSURFA.2018.07.005
Polyelectrolyte-coated nanocapsules containing cyclosporine A protect neuronal-like cells against oxidative stress-induced cell damage
M. Piotrowski (2018)
10.3109/03639045.2016.1171335
Nanoparticles as tool for enhanced ophthalmic delivery of vancomycin: a multidistrict-based microbiological study, solid lipid nanoparticles formulation and evaluation
Carol Yousry (2016)
NANOTECHNOLOGY: A NEW APPROACH FOR OCULAR DRUG DELIVERY SYSTEM
Meetali Mudgil (2012)
10.1111/jphp.12132
Topical delivery of ocular therapeutics: carrier systems and physical methods
J. G. Souza (2014)
10.3109/10717544.2013.834417
Development, in vitro and in vivo characterization of Eudragit RL 100 nanoparticles for improved ocular bioavailability of acetazolamide
P. Verma (2013)
10.2147/IJN.S122747
A novel ion-exchange carrier based upon liposome-encapsulated montmorillonite for ophthalmic delivery of betaxolol hydrochloride
Y. Huang (2017)
10.2174/1876402911204020128
Viability of Nanotechnology in Ocular Therapeutics
Mukesh K. Pathak (2012)
10.1007/978-3-319-47691-9
Ocular Drug Delivery: Advances, Challenges and Applications
Richard T. Addo (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar